Abstract
Treatment of sporadic cardiac myxoma (CM) has always been a challenging task. Currently, surgical excision remains the only option; however, targeted drug discovery schemes are in progress in order to improve treatment strategies and efficacy. The molecular mechanisms behind CM pathogenesis are still not totally unveiled thus drug target identification is still at early steps, trying to compile structured data on the pathophysiology of CM, targets and targeting moieties. Five critical disease pathways involving molecules of seven functional groups have been recently shown by us to be associated with the pathogenesis of CM. In addition, 15 to 20 drug targets and their targeting molecules have also mapped on pathways in an effort to start decoding the molecular profiles based on which early efforts for CM patient stratification into targeted therapeutic regimes. The present review describes the current data and discusses critical issues in the field of targeted and personalized medicine of CM.
Keywords: Critical disease pathways, cardiac myxoma markers, drug targets, targeted therapy
Current Cancer Drug Targets
Title: Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma
Volume: 9 Issue: 6
Author(s): Debmalya Barh, Anil Kumar, Suvro Chatterjee and Triantafillos Liloglou
Affiliation:
Keywords: Critical disease pathways, cardiac myxoma markers, drug targets, targeted therapy
Abstract: Treatment of sporadic cardiac myxoma (CM) has always been a challenging task. Currently, surgical excision remains the only option; however, targeted drug discovery schemes are in progress in order to improve treatment strategies and efficacy. The molecular mechanisms behind CM pathogenesis are still not totally unveiled thus drug target identification is still at early steps, trying to compile structured data on the pathophysiology of CM, targets and targeting moieties. Five critical disease pathways involving molecules of seven functional groups have been recently shown by us to be associated with the pathogenesis of CM. In addition, 15 to 20 drug targets and their targeting molecules have also mapped on pathways in an effort to start decoding the molecular profiles based on which early efforts for CM patient stratification into targeted therapeutic regimes. The present review describes the current data and discusses critical issues in the field of targeted and personalized medicine of CM.
Export Options
About this article
Cite this article as:
Barh Debmalya, Kumar Anil, Chatterjee Suvro and Liloglou Triantafillos, Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma, Current Cancer Drug Targets 2009; 9 (6) . https://dx.doi.org/10.2174/156800909789271549
DOI https://dx.doi.org/10.2174/156800909789271549 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Nanoparticles as Drug Delivery Systems for Cancer Treatment
Current Nanoscience From Discovery to the Coming Generation of Histone Deacetylase Inhibitors
Current Medicinal Chemistry High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC
Current Molecular Medicine Tumor-Induced Alterations in Lipid Metabolism
Current Medicinal Chemistry Using Protein-protein Interaction Network Information to Predict the Subcellular Locations of Proteins in Budding Yeast
Protein & Peptide Letters Analysis of Clinicopathological Characteristics and Prognosis of 1425 Primary Breast Cancer Patients in Eastern Guangdong, China
Current Signal Transduction Therapy Selectivity Filters to Edit Out Deleterious Side Effects in Kinase Inhibitors
Current Topics in Medicinal Chemistry New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology
Current Radiopharmaceuticals Actinic Keratosis: Review of the Literature and New Patents
Recent Patents on Inflammation & Allergy Drug Discovery Skeletal Effects of Drugs to Treat Cancer
Current Drug Safety Performance Analysis of Brain Tumor Detection based on Fuzzy Logic and Neural Network Classifier
Current Medical Imaging Microwave Synthesis of Guanine and Purine Analogs
Current Microwave Chemistry One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology The Therapeutic Properties of Carapa guianensis
Current Pharmaceutical Design Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers Meet Our Editor-in-Chief
Clinical Cancer Drugs Combination of Multifunctional Nanoparticles and Interventional Techniques Makes Each Other Going Further in the Field of Cancer Treatment
Current Drug Metabolism Telomere End Protection in Stem Cells and Cancer Cells
Current Cancer Therapy Reviews New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry